Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHA:600381)
China · Delayed Price · Currency is CNY 5.12
-0.06 (-1.16%)
Jul 3, 2026, 3:00 PM CST
SHA:600381 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 299.28 | 339.03 | 264.68 | 206.78 | 155.05 | 123.89 |
Other Revenue | 4.39 | 4.39 | 5.58 | 7.09 | 5.13 | 3.88 |
| 303.67 | 343.42 | 270.26 | 213.88 | 160.18 | 127.76 | |
Revenue Growth (YoY) | 12.75% | 27.07% | 26.36% | 33.52% | 25.37% | 2.81% |
Cost of Revenue | 206.83 | 212.07 | 203.49 | 86.27 | 138.5 | 147.78 |
Gross Profit | 96.83 | 131.35 | 66.77 | 127.61 | 21.68 | -20.02 |
Selling, General & Admin | 121.31 | 129.47 | 193.44 | 222.37 | 188.41 | 118.56 |
Research & Development | 6.38 | 9.77 | 14.56 | 11.64 | 11.38 | 9.54 |
Other Operating Expenses | 3.91 | 4.49 | 4.33 | 3.08 | 2.93 | 3.19 |
Operating Expenses | 136.83 | 148.96 | 223.16 | 246.81 | 229.43 | 189.87 |
Operating Income | -40 | -17.6 | -156.39 | -119.2 | -207.75 | -209.89 |
Interest Expense | -0.15 | -0.21 | -0.67 | -0.91 | -0.09 | -0.05 |
Interest & Investment Income | 14.29 | 13.09 | 1.13 | 1.36 | 0.5 | 0.17 |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | 2.64 | -0.13 | -0.88 | 1.33 |
Other Non Operating Income (Expenses) | -1.56 | -0.73 | 1.22 | -0.31 | -0.52 | 5.79 |
EBT Excluding Unusual Items | -27.46 | -5.51 | -152.07 | -119.2 | -208.74 | -202.64 |
Gain (Loss) on Sale of Investments | -9.88 | -9.9 | -36.9 | -139.81 | -46.96 | -51.13 |
Gain (Loss) on Sale of Assets | -0.02 | 0.02 | -0.11 | 0 | 0.02 | -0.02 |
Asset Writedown | -13.66 | -13.66 | -7.9 | -0.03 | -40.68 | - |
Legal Settlements | - | - | - | - | - | -0.02 |
Other Unusual Items | 4.05 | 4.04 | -4.23 | -1.25 | 1.09 | 1.35 |
Pretax Income | -46.97 | -25.02 | -201.2 | -260.28 | -295.27 | -252.46 |
Income Tax Expense | 14.34 | 11.06 | -3.89 | 5.93 | -7.72 | -3.84 |
Earnings From Continuing Operations | -61.31 | -36.08 | -197.31 | -266.21 | -287.55 | -248.61 |
Minority Interest in Earnings | -1.2 | -1.24 | -1.46 | -1.65 | 0 | - |
Net Income | -62.51 | -37.32 | -198.77 | -267.87 | -287.55 | -248.61 |
Net Income to Common | -62.51 | -37.32 | -198.77 | -267.87 | -287.55 | -248.61 |
Shares Outstanding (Basic) | 529 | 533 | 585 | 582 | 587 | 592 |
Shares Outstanding (Diluted) | 529 | 533 | 585 | 582 | 587 | 592 |
Shares Change (YoY) | -8.96% | -8.80% | 0.39% | -0.77% | -0.86% | 0.03% |
EPS (Basic) | -0.12 | -0.07 | -0.34 | -0.46 | -0.49 | -0.42 |
EPS (Diluted) | -0.12 | -0.07 | -0.34 | -0.46 | -0.49 | -0.42 |
Free Cash Flow | 26.44 | -32.96 | 76.04 | 10.39 | -32.64 | -185.73 |
Free Cash Flow Per Share | 0.05 | -0.06 | 0.13 | 0.02 | -0.06 | -0.31 |
Gross Margin | 31.89% | 38.25% | 24.71% | 59.67% | 13.53% | -15.67% |
Operating Margin | -13.17% | -5.13% | -57.86% | -55.73% | -129.70% | -164.28% |
Profit Margin | -20.59% | -10.87% | -73.55% | -125.24% | -179.52% | -194.59% |
Free Cash Flow Margin | 8.71% | -9.60% | 28.14% | 4.86% | -20.38% | -145.37% |
EBITDA | -24.36 | -1.03 | -136.06 | -97.52 | -167.01 | -168.29 |
EBITDA Margin | -8.02% | -0.30% | -50.34% | -45.60% | -104.27% | -131.72% |
D&A For EBITDA | 15.64 | 16.57 | 20.32 | 21.68 | 40.74 | 41.59 |
EBIT | -40 | -17.6 | -156.39 | -119.2 | -207.75 | -209.89 |
EBIT Margin | -13.17% | -5.13% | -57.86% | -55.73% | -129.70% | -164.28% |
Revenue as Reported | 303.67 | 343.42 | 270.26 | 213.88 | 160.18 | 127.76 |
Advertising Expenses | - | 26.73 | 69.63 | 79.8 | - | 24.65 |